2026年1月18日，百济神州自主研发的新型BCL2抑制剂索托克拉（百悦达）全国上市仪式暨《中国慢性淋巴细胞白血病（CLL）诊疗提升白皮书》2.0项目（以下简称“CLL白皮书2.0”）启动会同期正式举行。全国多位血液肿瘤领域权威专家受邀参与媒体访谈， ...
2026 年 1 月 12 日，由北京鸿远慈善基金会发起的「中外云端共话大咖智慧交融・血液肿瘤诊疗进展线上研讨会项目」慢性淋巴细胞白血病（CLL）有限期治疗以及微小残留病（MRD）检测前沿进展专场圆满落幕。中外顶级专家聚焦 CLL ...
In an interview during ASH 2025, Ontada's Ira Zackson, MD explores the role of BTK inhibitors in chronic lymphocytic leukemia ...
Two distinct subtypes, U-CLL C1 and U-CLL C2, were identified within IGHV-unmutated chronic lymphocytic leukemia, showing ...
The U.S. Food and Drug Administration (FDA) has approved Brukinsa (zanubrutinib) for the treatment of the blood and bone cancers known as chronic lymphocytic leukemia (CLL) and small lymphocytic ...
Germline Genetic Testing for Women With Breast Cancer: Shifting the Paradigm From Whom to Test to Whom NOT to Test In the article accompanying this editorial, ELEVATE RR study is a phase III, ...
Chronic lymphocytic leukemia (CLL) cell–derived exosomes demonstrated the ability to alter healthy donor cell function and suppress normal blood cell formation. These particles affected monocytes, ...
Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果